MNTA – Nice rebound today but meaningless in the overall scheme of things, IMHO. If the only impediment to approval of generic Lovenox turns out to be something straightforward, the stock will go bonkers. That’s a big if, of course, but we’re not talking about a mere double or triple here—we’re talking about a 10-bagger.
Moreover, if things don’t work out for generic Lovenox, MNTA’s other programs, especially M118, are IMO worth much more than the current valuation.
Market Data 
Markets 
AI
